.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Patients who do not respond adequately to triptans have limited acute-treatment options, particularly when poor response is due to efficacy rather than intolerance. The CENTURION study included a prespecified analysis of patients with insufficient triptan response and evaluated lasmiditan over repeated attacks. Lasmiditan 100 mg and 200 mg were superior to placebo for early pain freedom, pain relief, freedom from the most bothersome symptom and reduced need for rescue medication. The analysis also found consistency of effect across multiple attacks, suggesting that benefit was not confined to an isolated successful episode. The study is relevant to clinical practice because it addresses a common real-world problem rather than treatment-naive migraine. For HCPs, the findings support considering lasmiditan when prior triptans have not delivered adequate relief, while recognising the drug's CNS adverse effects. Patients should be counselled about dizziness, somnolence and activity restrictions after dosing. The broader message is that failure of one acute migraine mechanism does not mean all future acute therapies will fail; alternative pathways can still provide meaningful benefit.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Patients who do not respond adequately to triptans have limited acute-treatment options, particularly when poor response is due to efficacy rather than intolerance. The CENTURION study included a prespecified analysis of patients with insufficient triptan response and evaluated lasmiditan over repeated attacks. Lasmiditan 100 mg and 200 mg were superior to placebo for early pain freedom, pain relief, freedom from the most bothersome symptom and reduced need for rescue medication. The analysis also found consistency of effect across multiple attacks, suggesting that benefit was not confined to an isolated successful episode. The study is relevant to clinical practice because it addresses a common real-world problem rather than treatment-naive migraine. For HCPs, the findings support considering lasmiditan when prior triptans have not delivered adequate relief, while recognising the drug's CNS adverse effects. Patients should be counselled about dizziness, somnolence and activity restrictions after dosing. The broader message is that failure of one acute migraine mechanism does not mean all future acute therapies will fail; alternative pathways can still provide meaningful benefit.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
